{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:35:39Z","timestamp":1790775339991,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: The incidence of metabolic-dysfunction-associated steatotic liver disease (MASLD) is on the rise worldwide. The purpose of this paper is to review the current and emerging trends in the management and treatment of this condition. Methods: A comprehensive literature review was conducted using PubMed and GoogleScholar, focusing on articles published within the last ten years. Results: As the incidence of MASLD rises worldwide, it is becoming ever more important to call attention to disease prevention and progression. Although weight loss, diet, and exercise play a major role, certain therapies including GLP-1 receptor agonists, resmetirom, lanifibranor, and FGF-3 analogs are showing promise when treating patients with MASLD. As more drugs become available, it will be important to note how these medications change the global outlook of this disease. Conclusions: Overall, the treatment landscape of MASLD is rapidly changing. Several phase 3 trials have revealed promising data when it comes to improving liver fibrosis and histology. This shift in treatment will provide new hope for patients and clinicians when treating this challenging disease.<\/jats:p>","DOI":"10.3390\/jcm14176060","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:31:12Z","timestamp":1756373472000},"page":"6060","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5851-6688","authenticated-orcid":false,"given":"Pranav","family":"Patel","sequence":"first","affiliation":[{"name":"Prisma Health Greenville Memorial Hospital, Greenville, SC 29605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Abdelhameed, F., Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Than, N.N., Kassi, E., Kyrou, I., and Randeva, H.S. (2025). Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications. Livers, 5.","DOI":"10.3390\/livers5010011"},{"key":"ref_4","first-page":"1179","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Younossi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_5","unstructured":"Kudaravalli, P., and John, S. (2025, May 21). Nonalcoholic Fatty Liver, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541033\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3748\/wjg.v29.i32.4831","article-title":"Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments","volume":"29","author":"Petagine","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e0108","DOI":"10.1097\/HC9.0000000000000108","article-title":"American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease","volume":"7","author":"Stine","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","article-title":"Bariatric-metabolic surgery vs. lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): A multi-centre, open-label, randomized trial","volume":"401","author":"Verrastro","year":"2023","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e237188","DOI":"10.1001\/jamanetworkopen.2023.7188","article-title":"Cardiovascular Outcomes and Mortality After Bariatric Surgery in Patients With Nonalcoholic Fatty Liver Disease and Obesity","volume":"6","author":"Krishnan","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"ref_13","first-page":"e76716","article-title":"Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options","volume":"17","author":"Koullias","year":"2025","journal-title":"Cureus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tips.2022.11.001","article-title":"Obesity pharmacotherapy: Incretin action in the central nervous system","volume":"44","author":"Boer","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aronne, L.J., Horn, D.B., le Roux, C.W., Ho, W., Falcon, B.L., Valderas, E.G., Das, S., Lee, C.J., Glass, L.C., and Senyucel, C. (N. Engl. J. Med., 2025). SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, N. Engl. J. Med., ahead of print.","DOI":"10.1056\/NEJMoa2416394"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care."},{"key":"ref_18","unstructured":"Boehringer Ingelheim (2025, July 03). Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two Phase III Trials in MASH for Survodutide. Available online: https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.3748\/wjg.v30.i48.5205","article-title":"GLP-1, GIP\/GLP-1, and GCGR\/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis","volume":"30","author":"Singh","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Aldhaleei, W.A., Abegaz, T.M., and Bhagavathula, A.S. (2024). Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals, 17.","DOI":"10.3390\/ph17020199"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_23","unstructured":"Chopra, S., and Lai, M. (2025, July 03). Management of Metabolic Dysfunction Associated Steatotic Liver Disease (Nonalcoholic Fatty Liver Disease) in Adults. UpToDate. Updated 9 February 2025. Available online: https:\/\/www.uptodate.com\/contents\/management-of-metabolic-dysfunction-associated-steatotic-liver-disease-nonalcoholic-fatty-liver-disease-in-adults?."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., and Pliouta, L. (2025). The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020428"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ong Lopez, A.M.C., and Pajimna, J.A.T. (2024). Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-52603-5"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Perumpail, B.J., Li, A.A., John, N., Sallam, S., Shah, N.D., Kwong, W., Cholankeril, G., Kim, D., and Ahmed, A. (2018). The Role of Vitamin E in the Treatment of NAFLD. Diseases, 6.","DOI":"10.3390\/diseases6040086"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101939","DOI":"10.1016\/j.xcrm.2025.101939","article-title":"Chinese NAFLD Clinical Research Network (CNAFLD CRN). Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study","volume":"6","author":"Song","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_29","first-page":"e72596","article-title":"Vitamin E and Non-alcoholic Fatty Liver Disease: Investigating the Evidence Through a Systematic Review","volume":"16","author":"Abera","year":"2024","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"ref_31","unstructured":"Inventiva (2025, July 03). Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH. Sofinnova Partners. 12 October 2020. Available online: https:\/\/sofinnovapartners.com\/news\/inventiva-receives-fda-breakthrough-therapy-designation-for-lead-drug-candidate-lanifibranor-in-nash?utm_source=chatgpt.com."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_33","unstructured":"Inventiva (2025, July 03). Inventiva Announces Completion of Enrollment in the Phase 3 NATiV3 Clinical Trial of Lanifibranor in Patients with MASH and Advanced Fibrosis; BioSpace (Daix, France): 2025. Available online: https:\/\/www.biospace.com\/press-releases\/inventiva-announces-completion-of-enrollment-in-the-phase-3-nativ3-clinical-trial-of-lanifibranor-in-patients-with-mash-and-advanced-fibrosis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3748\/wjg.v26.i3.279","article-title":"Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma","volume":"26","author":"Ocker","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Noureddin, M., Rinella, M.E., Chalasani, N.P., Neff, G.W., Lucas, K.J., Rodriguez, M.E., Rudraraju, M., Patil, R., Behling, C., and Burch, M. (N. Engl. J. Med., 2025). Efruxifermin in Compensated Liver Cirrhosis Caused by MASH, N. Engl. J. Med., ahead of print.","DOI":"10.1056\/NEJMoa2502242"},{"key":"ref_37","unstructured":"Akero Therapeutics (2025, June 22). Clinical Trials\u2014Efruxifermin for MASH. Akero Therapeutics Website. Available online: https:\/\/akerotx.com\/clinical-trials\/."},{"key":"ref_38","unstructured":"Akero Therapeutics (2025, June 22). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic NASH\/MASH and fibrosis (ClinicalTrials.gov Identifier: NCT06215716), Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102357","DOI":"10.1016\/j.clinre.2024.102357","article-title":"Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Marey","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6060\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:53Z","timestamp":1760034833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/17\/6060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":39,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14176060"],"URL":"https:\/\/doi.org\/10.3390\/jcm14176060","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}